CANbridge Pharmaceuticals Data on  CAN106, to be Presented at Two Conferences

Complement C5 Antibody, CAN106, in Phase 1b/2 China Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Sep 22, 2022

CANbridge Pharmaceuticals to Participate in Two Investor Conferences in September

Sep 13, 2022

CANbridge Pharmaceuticals Presented at the Jefferies Asia Forum

Sep 11, 2022

CANbridge Announces Financial Results and Corporate Updates for Six Months Ended June 30, 2022

Aug 24, 2022

First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2   Trial for the Treatment of Gaucher Disease in China

Jul 20, 2022

First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China

  -  China Study is Part of Global EMBARK Study

Jul 14, 2022

CANbridge Forms Scientific Advisory Board to Guide Global Development of CAN106 in Complement-mediated Diseases

Jul 06, 2022

CANbridge Appoints Industry Leader Edward Hu to the Board

Jul 05, 2022

CANbridge CAN106 Phase 1 Data Presented at the European Hematology Association 2022 Congress

Jun 10, 2022